secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2022-04-27T23:59:59+00:00
Accession:  0000318154-22-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q1 revenues up 6% to $6.2B; Non-GAAP EPS $4.25, +15%; reaffirms 2022 guide
--------------------------------------------------------------------------------

- Total revenues $6.2B (+6% YoY); product sales grew 2% with double-digit volume growth for Repatha, Prolia, EVENITY.
- GAAP EPS $2.68 (-5%); Non-GAAP EPS $4.25 (+15%) on revenue growth and lower share count.
- GAAP operating income $2.5B (+17%); Non-GAAP operating margin 54.8% (+3.6 ppts).
- Free cash flow $2.0B vs $1.9B in Q1 2021.
- 2022 guidance: revenue $25.4-26.5B; GAAP EPS $12.53-13.58; Non-GAAP EPS $17-18 reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815422000019/0000318154-22-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815422000019/amgn-20220427.htm
  HTML page:      https://secwatch.observer/filing/0000318154-22-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer